Selection of potential targets for stratifying congenital pulmonary airway malformation patients with molecular imaging : is MUC1 the one?
Copyright ©The authors 2023..
Currently there is a global lack of consensus about the best treatment for asymptomatic congenital pulmonary airway malformation (CPAM) patients. The somatic KRAS mutations commonly found in adult lung cancer combined with mucinous proliferations are sometimes found in CPAM. For this risk of developing malignancy, 70% of paediatric surgeons perform a resection for asymptomatic CPAM. In order to stratify these patients into high- and low-risk groups for developing malignancy, a minimally invasive diagnostic method is needed, for example targeted molecular imaging. A prerequisite for this technique is a cell membrane bound target. The aim of this study was to review the literature to identify potential targets for molecular imaging in CPAM patients and perform a first step to validate these findings.A systematic search was conducted to identify possible targets in CPAM and adenocarcinoma in situ (AIS) patients. The most interesting targets were evaluated with immunofluorescent staining in adjacent lung tissue, KRAS+ CPAM tissue and KRAS- CPAM tissue.In 185 included studies, 143 possible targets were described, of which 20 targets were upregulated and membrane-bound. Six of them were also upregulated in lung AIS tissue (CEACAM5, E-cadherin, EGFR, ERBB2, ITGA2 and MUC1) and as such of possible interest. Validating studies showed that MUC1 is a potential interesting target.This study provides an extensive overview of all known potential targets in CPAM that might identify those patients at risk for malignancy and conducted the first step towards validation, identifying MUC1 as the most promising target.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
European respiratory review : an official journal of the European Respiratory Society - 32(2023), 170 vom: 31. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
van Horik, Cathy [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
EC 3.6.5.2 |
|---|
| Anmerkungen: |
Date Completed 22.12.2023 Date Revised 30.12.2023 published: Electronic-Print Citation Status MEDLINE |
|---|
| doi: |
10.1183/16000617.0217-2023 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366138987 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366138987 | ||
| 003 | DE-627 | ||
| 005 | 20240108140241.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1183/16000617.0217-2023 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1243.xml |
| 035 | |a (DE-627)NLM366138987 | ||
| 035 | |a (NLM)38123235 | ||
| 035 | |a (PII)230217 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a van Horik, Cathy |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Selection of potential targets for stratifying congenital pulmonary airway malformation patients with molecular imaging |b is MUC1 the one? |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.12.2023 | ||
| 500 | |a Date Revised 30.12.2023 | ||
| 500 | |a published: Electronic-Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright ©The authors 2023. | ||
| 520 | |a Currently there is a global lack of consensus about the best treatment for asymptomatic congenital pulmonary airway malformation (CPAM) patients. The somatic KRAS mutations commonly found in adult lung cancer combined with mucinous proliferations are sometimes found in CPAM. For this risk of developing malignancy, 70% of paediatric surgeons perform a resection for asymptomatic CPAM. In order to stratify these patients into high- and low-risk groups for developing malignancy, a minimally invasive diagnostic method is needed, for example targeted molecular imaging. A prerequisite for this technique is a cell membrane bound target. The aim of this study was to review the literature to identify potential targets for molecular imaging in CPAM patients and perform a first step to validate these findings.A systematic search was conducted to identify possible targets in CPAM and adenocarcinoma in situ (AIS) patients. The most interesting targets were evaluated with immunofluorescent staining in adjacent lung tissue, KRAS+ CPAM tissue and KRAS- CPAM tissue.In 185 included studies, 143 possible targets were described, of which 20 targets were upregulated and membrane-bound. Six of them were also upregulated in lung AIS tissue (CEACAM5, E-cadherin, EGFR, ERBB2, ITGA2 and MUC1) and as such of possible interest. Validating studies showed that MUC1 is a potential interesting target.This study provides an extensive overview of all known potential targets in CPAM that might identify those patients at risk for malignancy and conducted the first step towards validation, identifying MUC1 as the most promising target | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Proto-Oncogene Proteins p21(ras) |2 NLM | |
| 650 | 7 | |a EC 3.6.5.2 |2 NLM | |
| 650 | 7 | |a MUC1 protein, human |2 NLM | |
| 650 | 7 | |a Mucin-1 |2 NLM | |
| 700 | 1 | |a Zuidweg, Marius J P |e verfasserin |4 aut | |
| 700 | 1 | |a Boerema-de Munck, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Buscop-van Kempen, Marjon |e verfasserin |4 aut | |
| 700 | 1 | |a Brosens, Erwin |e verfasserin |4 aut | |
| 700 | 1 | |a Vahrmeijer, Alexander L |e verfasserin |4 aut | |
| 700 | 1 | |a von der Thüsen, Jan H |e verfasserin |4 aut | |
| 700 | 1 | |a Wijnen, René M H |e verfasserin |4 aut | |
| 700 | 1 | |a Rottier, Robbert J |e verfasserin |4 aut | |
| 700 | 1 | |a Tummers, Willemieke S F J |e verfasserin |4 aut | |
| 700 | 1 | |a Schnater, J Marco |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European respiratory review : an official journal of the European Respiratory Society |d 1997 |g 32(2023), 170 vom: 31. Dez. |w (DE-627)NLM090674383 |x 1600-0617 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2023 |g number:170 |g day:31 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1183/16000617.0217-2023 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2023 |e 170 |b 31 |c 12 | ||